IRIS
ARMUZZI, ALESSANDRO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.693
AS - Asia 5.212
EU - Europa 2.248
SA - Sud America 1.482
AF - Africa 165
Continente sconosciuto - Info sul continente non disponibili 2
OC - Oceania 1
Totale 18.803
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.556
SG - Singapore 3.476
BR - Brasile 1.299
CN - Cina 851
FI - Finlandia 536
IE - Irlanda 414
DE - Germania 254
VN - Vietnam 247
FR - Francia 231
IN - India 181
GB - Regno Unito 168
HK - Hong Kong 142
IT - Italia 135
NL - Olanda 133
RU - Federazione Russa 106
NG - Nigeria 71
AR - Argentina 65
CA - Canada 57
SE - Svezia 56
MX - Messico 51
BD - Bangladesh 48
TR - Turchia 37
BE - Belgio 36
IQ - Iraq 36
ZA - Sudafrica 36
EC - Ecuador 35
PL - Polonia 35
JP - Giappone 31
CZ - Repubblica Ceca 26
IR - Iran 24
ID - Indonesia 23
UA - Ucraina 21
ES - Italia 20
VE - Venezuela 19
IL - Israele 18
SA - Arabia Saudita 17
CO - Colombia 16
PK - Pakistan 16
UZ - Uzbekistan 16
CL - Cile 15
LT - Lituania 14
PY - Paraguay 13
MA - Marocco 12
AT - Austria 11
PE - Perù 11
TN - Tunisia 11
EG - Egitto 10
KE - Kenya 7
KZ - Kazakistan 7
AE - Emirati Arabi Uniti 6
CH - Svizzera 6
DO - Repubblica Dominicana 6
ET - Etiopia 6
UY - Uruguay 6
AL - Albania 5
EE - Estonia 5
HN - Honduras 5
JM - Giamaica 5
LB - Libano 5
RO - Romania 5
BG - Bulgaria 4
BY - Bielorussia 4
GT - Guatemala 4
JO - Giordania 4
KG - Kirghizistan 4
LV - Lettonia 4
PT - Portogallo 4
TT - Trinidad e Tobago 4
AZ - Azerbaigian 3
BO - Bolivia 3
CI - Costa d'Avorio 3
DZ - Algeria 3
GR - Grecia 3
BA - Bosnia-Erzegovina 2
BH - Bahrain 2
BN - Brunei Darussalam 2
DK - Danimarca 2
KW - Kuwait 2
LU - Lussemburgo 2
NP - Nepal 2
OM - Oman 2
PH - Filippine 2
TG - Togo 2
TW - Taiwan 2
XK - ???statistics.table.value.countryCode.XK??? 2
AM - Armenia 1
AO - Angola 1
AU - Australia 1
BF - Burkina Faso 1
BW - Botswana 1
CR - Costa Rica 1
GD - Grenada 1
HU - Ungheria 1
IS - Islanda 1
KH - Cambogia 1
LA - Repubblica Popolare Democratica del Laos 1
MK - Macedonia 1
ML - Mali 1
NO - Norvegia 1
PA - Panama 1
Totale 18.796
Salva come PNG Salva come JPEG
Città #
Chandler 1.802
Singapore 1.088
The Dalles 981
Dallas 886
Ashburn 728
Shanghai 617
Helsinki 533
Dublin 414
Boardman 398
Lawrence 390
Princeton 390
New York 261
Paris 209
Los Angeles 189
Wilmington 184
Hong Kong 134
Beijing 128
Amsterdam 127
São Paulo 114
Pune 113
London 93
Ho Chi Minh City 91
Santa Clara 73
Benin City 68
San Mateo 65
Hanoi 57
Council Bluffs 56
Seattle 55
Rio de Janeiro 53
Ann Arbor 49
Phoenix 42
Munich 40
Moscow 39
Belo Horizonte 35
Brussels 35
Milan 34
Warsaw 34
Brooklyn 33
Porto Alegre 30
Leawood 29
Brasília 27
Curitiba 25
Tokyo 25
Brno 22
Chennai 22
Toronto 21
Atlanta 20
Frankfurt am Main 20
San Francisco 20
Chicago 19
Fairfield 19
Mexico City 19
Montreal 19
Woodbridge 19
Boston 17
Goiânia 17
Johannesburg 17
Assago 16
Stockholm 16
Falkenstein 15
Guayaquil 15
Tashkent 15
Buffalo 14
Campinas 14
Charlotte 14
Ankara 13
Guarulhos 13
Poplar 13
Rome 13
Baghdad 12
Oshnaviyeh 12
Houston 11
Orem 11
Haiphong 10
Riyadh 10
Berlin 9
Dhaka 9
Fortaleza 9
Montes Claros 9
Mumbai 9
Osasco 9
Quito 9
Salvador 9
São Bernardo do Campo 9
Biên Hòa 8
Caracas 8
Columbus 8
Kocaeli 8
Manaus 8
Naples 8
Pelotas 8
São José dos Campos 8
Tunis 8
Betim 7
Botucatu 7
Denver 7
Joinville 7
Juiz de Fora 7
Manchester 7
Miami 7
Totale 11.484
Salva come PNG Salva come JPEG
Nome #
A 1-year follow-up study on checkpoint inhibitor-induced colitis: results from a European consortium 489
Gemelli decision tree Algorithm to Predict the need for home monitoring or hospitalization of confirmed and unconfirmed COVID-19 patients (GAP-Covid19): preliminary results from a retrospective cohort study 186
A liophylized and inactivated colture of Lactobacillus acidophilus increases Helicobacter pylori eradication rate 106
Adalimumab in active ulcerative colitis: A "real-life" observational study 98
Water supplementation enhances the effect of high-fiber diet on stool frequency and laxative consumption in adult patients with functional constipation 97
A machine-learning parsimonious multivariable predictive model of mortality risk in patients with Covid-19 93
13C-breath tests in the study of mitochondrial liver function 92
13C-Breath Tests in the study of microsomal liver function 87
Are we choosing wisely for inflammatory bowel disease care? The IG-IBD choosing wisely campaign 85
Activities related to inflammatory bowel disease management during and after the coronavirus disease 2019 lockdown in Italy: How to maintain standards of care 78
Achievement of sustained deep remission with adalimumab in a patient with both refractory ulcerative colitis and seronegative erosive rheumatoid arthritis 77
DNA mismatch repair gene mutations in hereditary non polyposis colorectal cancer (HNPCC) and putative HNPCC (P-HNPCC) Italian families 75
3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management 74
Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) 73
A case of pyoderma gangrenosum with ulcerative colitis treated with combined approach: infliximab and surgery 71
A lyophilized and inactivated culture of Lactobacillus acidophilus increases Helicobacter pylori eradication rates 70
Acute pancreatitis and parathyroid carcinoma: a case report and literature review 69
Effectiveness of Mesalazine, Thiopurines and Tumour Necrosis Factor Antagonists in Preventing Post-Operative Crohn's Disease Recurrence in a Real-Life Setting 68
Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease 68
3-day antibiotic therapy with azithromycin and tinidazole plus lansoprazole or pantoprazole to cure H-pylori infection 67
Adalimumab in the treatment of immune-mediated diseases 66
An Objective Comparison of Vedolizumab and Ustekinumab Effectiveness in Crohn's Disease Patients' Failure to TNF-Alpha Inhibitors 65
Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: An IG-IBD study 65
A transition clinic model for inflammatory bowel disease between two tertiary care centers: outcomes and predictive factors 64
H-pylori poliantibiotic resistant strains in dyspeptic patients not eradicated by two consecutive triple eradication regimens 64
Use of corticosteroids and immunosuppressive drugs in inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease 63
Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial 63
Activity of Crohn's disease and small bowel contract-enhanced ultrasound findings 62
A novel pathogenic role for microvasculature in inflammatory bowel disease 61
FOXP3(+) T Regulatory Cell Modifications in Inflammatory Bowel Disease Patients Treated with Anti-TNF alpha Agents 61
Long-Term Safety of In Utero Exposure to Anti-TNFα Drugs for the Treatment of Inflammatory Bowel Disease: Results from the Multicenter European TEDDY Study 60
Discontinuation of Infliximab in Patients With Ulcerative Colitis Is Associated With Increased Risk of Relapse: A Multinational Retrospective Cohort Study 60
Anti TNF-α therapy for ulcerative colitis: current status and prospects for the future 59
Long-term scheduled therapy with infliximab in inflammatory bowel disease 59
Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease 58
Use of biosimilars in inflammatory bowel disease: Statements of the Italian Group for Inflammatory Bowel Disease 58
The role of tumour necrosis factor in the pathogenesis of immune-mediated diseases 57
H-pylori gastric infection and rheumatic diseases 56
Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: an IG-IBD study 56
Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study 56
A multistep assessment of human liver mitochondrial function through C-13-ketoisocaproate and C-13-octanoate breath tests 56
Dysfunctional Extracellular Matrix Remodeling Supports Perianal Fistulizing Crohn's Disease by a Mechanoregulated Activation of the Epithelial-to-Mesenchymal Transition 55
Hepatic mitochondrial beta-oxidation in patients with nonalcoholic steatohepatitis assessed by C-13-octanoate breath test 55
Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) 55
Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment 55
ECCO Guidelines on Therapeutics in Crohn's Disease: Surgical Treatment 55
Infliximab in Steroid-dependent Ulcerative Colitis: Effectiveness and Predictors of Clinical and Endoscopic Remission 55
Role of helicobacter pylori in gastroesophageal reflux disease 54
Difference in treatment outcomes between clinical trials and "real-life" clinical practice: ustekinumab in ulcerative colitis 54
Association of Depression With Incident Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis 54
Haplotypic analysis of heat shock protein 70 (HSP70) single nucleotide polymorphisms (SNPs) in susceptibility and phenotype of inflammatory bowel disease (IBD) 52
INFLAMMATORY BOWEL DISEASE (IBD) PATIENTS ON ANTI TNF-ALPHA THERAPY: RESPONSE TO THE INFLUENZA A/H1N1 VACCINE 52
Aminopyrine and methacetin 13C-breath tests to assess hepatic function in HCV-related chronic liver disease 52
Dual Targeted Therapy in Patient With Extensive Crohn's Disease: Different Response at Distinct Location 52
Risk factor analysis for therapy related adverse events and infections in elder patients with Inflammatory Bowel Disease; An analysis from the IG-IBD aged study 52
HELICOBACTER-PYLORI GASTRITIS WITH CYTOTOXIN ASSOCIATED PROTEIN ANTIBODIES (CAGA) - A COMPUTER-AIDED EVALUATION OF INFLAMMATORY CELL INFILTRATION IN THE LAMINA PROPRIA, ATROPHIC GASTRITIS AND ACQUIRED MALT 51
Antibiotic resistance of H-pylori strains obtained by dyspeptic patients not eradicated by two consecutive eradication regimens 51
Efficacy of a multistep strategy for Helicobacter pylori eradication 51
C-13 urea breath test for predicting resistance to therapy in Helicobacter pylori infection 51
Long-term Combination Therapy with Infliximab Plus Azathioprine Predicts Sustained Steroid-free Clinical Benefit in Steroid-dependent Ulcerative Colitis 51
Disease patterns in late-onset ulcerative colitis: Results from the " IG-IBD ""AGED study""" 51
The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar 51
The intercellular adhesion molecule-1 polymorphisms in IBD 50
Usefulness of C-13-methionine breath test as a non-invasive and dynamic tool to evaluate residual hepatic mitochondrial function 50
Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders 50
Helicobacter pylori eradication ameliorates migraine: An extended follow up study 50
Anti-CagA antibodies are associated with atrophic gastritis in a population at high gastric cancer risk: a morphometric study by computerized image analysis 50
IBD: Infliximab dose optimization in IBD-proactive or reactive? 50
Hepatic mitochondrial beta-oxidation in patients with Nonalcoholic-Steatohepatitis (NASH) assessed by 13C-octanoate breath test 50
Adherence to international guidelines for the management of Helicobacter pylori infection among gastroenterologists and gastroenterology fellows in Italy: A Survey of the Italian Federation of Digestive Diseases - FISMAD 50
Seroprevalence of hepatitis A virus and Helicobacter pylori infections in the general population of a developed European country (the San Marino study): evidence for similar pattern of spread 50
The PROSIT-BIO Cohort of the IG-IBD: A Prospective Observational Study of Patients With Inflammatory Bowel Disease Treated With Infliximab BioSimilars 50
Incidence and symptoms related to Helicobacter pylori infection in dyspeptic patients 49
Levofloxacin based regimens for the eradication of Helicobacter pylori 49
C-13-methionine breath tests for mitochondrial liver function assessment 49
C-13-methacetin breath test in patients with nonalcoholic steatohepatitis 49
New biological agents for the treatment of the "high risk" IBD patients 49
Can C-13 urea breath test predict resistance to therapy in Helicobacter pylori infection? 49
Mono, dual and triple moxifloxacin-based regimens for Helicobacter pylori eradication 49
Long-term outcomes of acute severe ulcerative colitis in the rescue therapy era: A multicentre cohort study 49
Non-invasive assessment of human hepatic mitochondrial function through the C-13-methionine breath test 49
Young GI angle: Should I go abroad? 48
Safety and efficacy of combining biologics or small molecules for inflammatory bowel disease or immune-mediated inflammatory diseases: A European retrospective observational study 48
Effectiveness of Third-Class Biologic Treatment in Crohn's Disease: A Multi-Center Retrospective Cohort Study 48
COVID-19 Vaccination Willingness and Hesitancy in Patients With Inflammatory Bowel Diseases: Analysis of Determinants in a National Survey of the Italian IBD Patients' Association 48
Family history of peptic ulcer and a positive C-13 urea breath test are predictive of gastroduodenal ulcer disease in uninvestigated dyspeptic patients 48
Infliximab in Steroid-Dependent Ulcerative Colitis 48
Prevalence and natural history of hepatitis B and C infections in a large population of IBD patients treated with anti-tumor necrosis factor-α agents 48
Ulcerative Colitis Narrative Global Survey Findings: Communication Gaps and Agreements Between Patients and Physicians 48
Role of sucralfate in gastrointestinal diseases 48
Higher vs Standard Adalimumab Induction Dosing Regimens and Two Maintenance Strategies: Randomized SERENE CD Trial Results 48
DISAPPEARANCE OF GASTRIC ACQUIRED MALT AND REGRESSION OF LOW-GRADE B-CLL GASTRIC LYMPHOMA BY MEAN ANTI-H-PYLORI TREATMENT 48
Treatment satisfaction, preferences and perception gaps between patients and physicians in the ulcerative colitis CARES study: A real world-based study 47
New developments in biologics therapy: what about from the medical point of view? 47
Advances in extracorporeal detoxification by MARS dialysis in patients with liver failure 47
Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease 47
Occurence of systemic endothelial dysfunction in patients affected by ulcerative colitis and Crohn disease 47
Successful induction of clinical response and remission with certolizumab pegol in Crohn's disease patients refractory or intolerant to infliximab: a real-life multicenter experience of compassionate use 47
Deep Remission at 1 Year Prevents Progression of Early Crohn's Disease 47
Impact of COVID-19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: Reorganisational response in a high-volume Italian inflammatory bowel disease centre 46
Totale 6.345
Salva come PNG Salva come JPEG
Categoria #
all - tutte 146.190
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 146.190
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021324 0 0 0 0 0 114 41 21 74 42 1 31
2021/2022227 6 2 11 43 3 0 7 24 19 19 50 43
2022/20235.208 842 55 423 571 430 547 7 531 960 455 333 54
2023/20243.336 219 318 781 260 112 383 184 108 26 217 337 391
2024/20254.554 95 27 49 56 40 441 222 293 905 1.252 598 576
2025/20265.259 1.818 830 895 1.068 461 187 0 0 0 0 0 0
Totale 18.927